Bob Hopkins

On Thursday, President Joe Biden revealed his new COVID-19 action plan, which includes $2 billion in government spending on 280 million rapid point of care and at-home COVID-19 tests. On Friday, Bank of America analyst Bob Hopkins said Biden’s new plan is good news for test manufacturers...

Rani Therapeutics Holdings, Inc. (NASDAQ: RANI), an early stage platform technology company that promotes oral dosing with its RaniPill, and RxSight, Inc. (NASDAQ: RXST), an ophthalmology-focused MedTech company, went public in late July. Here's what BofA Securities has to say about the newly...

Shockwave Medical Inc (NSDQ: SWAV) first-quarter FY21 sales more than double to $31.9 million beating the Wall Street consensus of $29.9 million. The growth was primarily driven by the launch of the coronary product, Shockwave C, in the U.S. in February and increased adoption of...

Smid-cap MedTech company ShockWave Medical Inc (NASDAQ: SWAV) has seen its shares appreciate over 120% year-to-date. The ShockWave Analyst: BofA Securities analyst Bob Hopkins downgraded ShockWave from Buy to Neutral, citing valuation. Given the recent appreciation in the peer group,...

Abbott Laboratories (NYSE: ABT) reported strong third-quarter results Wednesday and looks able to generate double-digit earnings growth going ahead, even without considering testing revenue, according to BofA Securities. The Abbott Laboratories Analyst: Bob Hopkins reiterated a Buy rating on...

Abbott Laboratories (NYSE: ABT) shares rallied Thursday after the company's rapid COVID-19 test received emergency use authorization from the FDA.    The Abbott Analyst: Bob Hopkins reiterated a Buy rating on Abbott Laboratories and increased the price target from $110 to $122....

Johnson & Johnson (NYSE: JNJ) shares are up 36.1% in the last three months amid a broad market recovery. While the near-term economic outlook is unclear given COVID-19 uncertainty, one large option trader made a big bet Wednesday that Johnson & Johnson shares are headed much higher in the...

Johnson & Johnson (NYSE: JNJ) just can't seem to shake its talcum powder problems. On Friday, Johnson & Johnson recalled 33,000 bottles of baby powder after a bottle purchased online by the FDA tested positive to asbestos. Last year, a jury awarded a group of 22 women $4.69 billion in a...

Johnson & Johnson (NYSE: JNJ) stock was on the rise Wednesday following better-than-expected third-quarter earnings and guidance, but analysts are mostly leery of boosting recommendations in light of a string of legal challenges the company faces. The Analysts Morgan Stanley’s...

Johnson & Johnson (NYSE: JNJ) shares are down 2% since the company reported a second-quarter earnings beat on Tuesday morning. Johnson & Johnson reported a 42% increase in net profit in the quarter. Revenue of $20.56 billion was down 1.3% from a year ago but also topped consensus analyst...

A Food and Drug Administration warning about possible dangers from balloons and stents coated with the drug paclitaxel is bad news for Boston Scientific Corporation (NYSE: BSX)’s Eluvia stent, but Bank of America Merrill Lynch is still recommending the stock on the basis of the company’...

Medical device maker Medtronic PLC (NYSE: MDT)'s rocketed higher after the company reported first-quarter earnings Tuesday. The Analyst Bank of America Merrill Lynch analyst Bob Hopkins reiterated a Buy rating  on Medtronic and increased the price target from $98 to $105. The...

Bank of America Merrill Lynch has started coverage of Nevro Corp (NYSE: NVRO) with a Buy rating and price objective of $100, implying a potential return of 24 percent. Nevro's Senza Spinal Cord Stimulation (SCS) system delivers HF10 (high frequency) therapy to treat patients suffering from chronic...

On Thursday, Bank of America Merrill Lynch issued a medical technology industry note highlighting HeartWare International Inc (NASDAQ: HTWR), Tandem Diabetes Care Inc (NASDAQ: TNDM) and EndoChoice Holdings Inc (NYSE: GI). Analysts Bob Hopkins and Travis Steed gave their opinion on the medical...